| Literature DB >> 29219177 |
Mohammad Jalili-Nik1,2, Arash Soltani1, Soussan Moussavi2, Majid Ghayour-Mobarhan3, Gordon A Ferns4, Seyed Mahdi Hassanian1,3, Amir Avan3,5.
Abstract
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide. Hence there is a need to identify new therapeutic agents that improve the current repertoire of chemotherapeutic drugs. The antitumor activity of curcumin has been reported for several tumors, including CRC. A recent phase I trial showed that curcumin is safe and tolerable adjunct to FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in patient-derived colorectal liver metastases at doses up to 2 g daily. Another trial revealed the effect of combining curcumin with FOLFOX in patients with inoperable colorectal cancer. The aim of current review was to summarize the current knowledge about possible molecular mechanisms of curcumin in CRC with particular emphasis on preclinical and early clinical studies of colorectal cancer.Entities:
Keywords: 5-FU; clinical trial; colorectal cancer; curumin
Mesh：
Substances：
Year: 2018 PMID： 29219177 DOI： 10.1002/jcp.26368
Source DB: PubMed Journal: J Cell Physiol ISSN： 0021-9541 Impact factor: 6.384